News Column

Reports Outline Cancer Gene Therapy Findings from S. Doktorovova and Colleagues (Cationic solid lipid nanoparticles interfere with the activity of...

August 4, 2014



Reports Outline Cancer Gene Therapy Findings from S. Doktorovova and Colleagues (Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells)

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators discuss new findings in Biotechnology. According to news reporting originating from Oporto, Portugal, by NewsRx correspondents, research stated, "Solid lipid nanoparticles (SLN) are colloidal drug and/or gene carriers developed from solid lipids and surfactants that are considered safe. Cationic SLN, usually used for formulating poorly water-soluble drugs and for gene delivery purposes, as positively charged particles may attach to cellular surfaces and be internalized more easily than negatively charged SLN, but they can also cause damage."

Our news editors obtained a quote from the research, "The main aim of this work was to test a set of cationic SLN and investigate its influence on the amount of reactive oxygen species (ROS), on antioxidant enzymes activities and on possible oxidative damage to membrane lipids in HepG2 cells. The Dichlorofluorescein assay revealed great increase in ROS presence after cell exposure to SLN. While the exposure to SLN increased the activities of superoxide dismutase and glutathione peroxidase it decreased glutathione reductase activity. Although no significant increase in thiobarbituric reactive species was found, a decrease in sulfhydryl groups was detected."

According to the news editors, the research concluded: "These results indicate that cationic SLN caused oxidative stress in HepG2 cells, but under reported exposure conditions HepG2 cells could attenuate the stress and thus the damage to cellular components was minimal."

For more information on this research see: Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells. International Journal of Pharmaceutics, 2014;471(1-2):18-27. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)

The news editors report that additional information may be obtained by contacting S. Doktorovova, Fernando Pessoa Univ, CEBIMED, Center Res Biomed, P-4249004 Oporto, Portugal. Additional authors for this research include D.L. Santos, I. Costa, T. Andreani, E.B. Souto and A.M. Silva (see also Biotechnology).

Keywords for this news article include: Antioxidants, Biotechnology, Oporto, Europe, Portugal, Oncology, Nanoparticle, Nanotechnology, Protective Agents, Cancer Gene Therapy, Emerging Technologies, Enzymes and Coenzymes, Hepatocellular Carcinoma

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters